GB-4362 / Generate Biomedicines - LARVOL DELTA

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials (FierceBiotech) - "The company has already earmarked $300 million of the IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895, which are expected to enroll about 1,600 patients...Generate expects an additional $100 million will be needed for its ambition to complete an ongoing phase 1b study of GB-0895 for chronic obstructive pulmonary disease and then to 'initiate the next phase of clinical development,' according to the filing...The biotech estimates $15 million of the proceeds will be needed to take GB-4362 and GB-5267 into the clinic."

Financing • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Solid Tumor